Chronic Immunosuppression & Biologic Therapies

NeuroWiki

Chronic Immunosuppression & Biologics

Chronic immunosuppression and biologic therapies form the backbone of long-term management across the spectrum of neuroimmunologic conditions. Maintenance immunotherapy is essential for preventing relapses and stepwise disability accrual in disorders such as NMOSD, MOGAD, autoimmune encephalitis, neurosarcoidosis, and neuropsychiatric SLE. The therapeutic landscape has expanded dramatically over the past decade, with three FDA-approved biologic agents now available for AQP4-positive NMOSD, high-efficacy disease-modifying therapies increasingly favored early in MS, and targeted biologics transforming the management of neurosarcoidosis. This topic provides a comprehensive overview of the oral immunosuppressants, biologic agents, and MS disease-modifying therapies used in neuroimmunology, along with practical guidance on treatment selection, monitoring, and long-term safety considerations.

Bottom Line

Maintenance immunotherapy prevents relapses and stepwise disability accrual in relapsing neuroimmune conditions — early initiation is critical in most disorders
Rituximab is the most widely used biologic across neuroimmunologic conditions (NMOSD, MOGAD, autoimmune encephalitis, neurosarcoidosis, CNS vasculitis)
Three FDA-approved NMOSD therapies: satralizumab (anti-IL-6R), inebilizumab (anti-CD19), and eculizumab (anti-C5) target specific pathogenic mechanisms in AQP4-positive disease
MS treatment: early high-efficacy therapy is increasingly favored over traditional escalation approaches; MS DMTs are contraindicated in NMOSD
Treatment selection depends on: underlying condition, antibody category, severity, side effect profile, comorbidities, cost, and patient preferences
Long-term monitoring for hypogammaglobulinemia, infection risk, and malignancy is essential for all patients on chronic immunosuppression

Oral Immunosuppressants

Conventional oral immunosuppressants remain widely used across neuroimmunologic conditions, particularly in resource-limited settings or as steroid-sparing agents. These medications are generally less expensive than biologics but require longer time to efficacy and carry distinct monitoring requirements. Most require 2–6 months to achieve full therapeutic effect, necessitating bridging therapy with corticosteroids or IVIg during the initiation period.

Mycophenolate Mofetil (MMF)

Mycophenolate mofetil selectively depletes guanosine nucleotides preferentially in T and B lymphocytes, inhibiting their proliferation. It is among the most commonly used oral immunosuppressants in neuroimmunology due to its relatively favorable safety profile and broad applicability.

Mycophenolate Mofetil — Key Points

Mechanism: Inhibits inosine monophosphate dehydrogenase (IMPDH), depleting guanosine nucleotides preferentially in T and B lymphocytes
Dosing (adults): 1000–3000 mg/day orally, divided twice daily
Dosing (pediatrics): 600 mg/m² twice daily, maximum 2 g/day
Time to efficacy: 2–3 months; bridge with corticosteroids or IVIg during initiation
Indications: NMOSD maintenance, MOGAD relapse prevention, autoimmune encephalitis maintenance, neuropsychiatric SLE, neurosarcoidosis
Pre-treatment screening: CBC, liver and renal function, pregnancy test (teratogenic — effective contraception required)
Monitoring: Regular CBC to detect myelosuppression
Adverse effects: Nausea, vomiting, diarrhea, myelosuppression, hypertension, teratogenicity, increased infection risk, increased malignancy risk

Azathioprine

Azathioprine is a purine synthesis inhibitor that suppresses immune cell proliferation. It has a long track record of use in neuroimmunology, particularly for NMOSD maintenance, though it has largely been supplanted by biologics in settings where these are available.

Azathioprine — Key Points

Mechanism: Purine synthesis inhibitor suppressing T-cell and B-cell proliferation
Dosing (adults): 1–3 mg/kg/day orally
Dosing (pediatrics): 2.5 mg/kg/day (for NMOSD)
Indications: NMOSD maintenance, MOGAD relapse prevention, neurosarcoidosis, autoimmune encephalitis
Pre-treatment screening: CBC, liver function, pregnancy screen, TPMT genotype
Monitoring: Regular CBC, liver function, TPMT levels
Adverse effects: Nausea, vomiting, myelosuppression, liver toxicity, rash, pancreatitis, increased infection risk, increased malignancy risk (particularly non-melanoma skin cancer, lymphoma)

TPMT Testing Before Azathioprine

TPMT (thiopurine methyltransferase) genotype must be checked BEFORE starting azathioprine
TPMT deficiency dramatically increases the risk of severe, potentially fatal myelosuppression
Homozygous TPMT deficiency (<1% of population): azathioprine is contraindicated
Heterozygous TPMT deficiency (~10% of population): requires significant dose reduction
Even with normal TPMT, regular CBC monitoring remains essential

Methotrexate

Methotrexate inhibits dihydrofolate reductase, disrupting folate metabolism and DNA synthesis. In neuroimmunology, its primary role is as a steroid-sparing agent in neurosarcoidosis, where it is increasingly used in combination with infliximab.

Methotrexate — Key Points

Mechanism: Dihydrofolate reductase inhibitor disrupting folate metabolism and DNA synthesis
Dosing: 10–25 mg/week orally or subcutaneously
Primary neuroimmunology indication: Neurosarcoidosis (steroid-sparing agent; commonly combined with infliximab)
Folic acid supplementation: 1 mg daily is required to reduce toxicity
Pre-treatment screening: CBC, liver and renal function, pregnancy screen (teratogenic)
Monitoring: Regular CBC, liver function, renal function, urinalysis
Additional benefit when combined with infliximab: Reduces formation of anti-infliximab antibodies, thereby maintaining drug efficacy
Adverse effects: Nausea, vomiting, fatigue, hair loss, elevated liver enzymes, myelosuppression, leukoencephalopathy, teratogenicity, infection risk

Hydroxychloroquine

Hydroxychloroquine is recommended in all patients with SLE. While it does not have specific CNS therapeutic benefit, it reduces overall SLE flare risk and has been associated with improved long-term outcomes including reduced organ damage, reduced thrombotic events, and improved survival. Its role in neuroimmunology is primarily as an adjunctive agent in the management of neuropsychiatric SLE.

Biologic Therapies

Biologic agents target specific immune pathways and have transformed the management of neuroimmunologic conditions. Biologics generally offer greater efficacy than conventional oral immunosuppressants but come with higher cost and specific monitoring requirements. The choice among biologics depends on the underlying condition, pathogenic antibody class, prior treatment response, and practical considerations including route of administration and cost.

Rituximab (Anti-CD20)

Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells, leading to B-cell depletion. It is the most widely used biologic across the spectrum of neuroimmunologic conditions and has the broadest evidence base for efficacy in these disorders. Worldwide, rituximab remains the most commonly prescribed maintenance therapy for NMOSD, where it achieves the lowest annualized relapse rate among conventional immunosuppressants.

Rituximab — Dosing and Monitoring

Adult dosing: 1000 mg IV × 2 infusions separated by 2 weeks, then repeat every 6 months
Pediatric dosing: 750 mg/m² × 2 infusions
Re-dosing strategy in NMOSD: B-cell counts can guide re-dosing intervals — patients relapse with B-cell repopulation; some clinicians monitor CD19+ or CD27+ cells rather than using fixed intervals
Pre-treatment screening: Hepatitis B (reactivation risk), Hepatitis C, TB (IGRA), quantitative immunoglobulins
Monitoring: Regular CBC, immunoglobulin levels (IgG, IgM); B-cell counts if using monitoring-based re-dosing
Duration: Condition-dependent; many patients require indefinite therapy

Rituximab indications across neuroimmunology include:

NMOSD: Most widely used maintenance therapy; ~60–70% of patients achieve relapse-free status; ~30% have breakthrough relapses prompting a switch to an alternative mechanism
MOGAD: Used for relapse prevention in patients with relapsing disease
Autoimmune encephalitis: Maintenance therapy, particularly for refractory or relapsing cases
Neurosarcoidosis: Alternative biologic, though infliximab is generally preferred
CNS vasculitis: Used in primary angiitis of the CNS (PACNS) and secondary vasculitis
IgG4-related disease: Effective for IgG4-related hypertrophic pachymeningitis and other manifestations
Neuropsychiatric SLE: Option for refractory disease

Rituximab — Hypogammaglobulinemia

Chronic B-cell depletion can lead to progressive hypogammaglobulinemia, particularly with prolonged use
Monitor quantitative immunoglobulin levels (IgG, IgM) at regular intervals
Patients with recurrent infections and low IgG may require immunoglobulin replacement therapy
Other important adverse effects: infusion reactions, PML (very rare), late-onset neutropenia

Inebilizumab (Anti-CD19)

Inebilizumab is a humanized monoclonal antibody targeting CD19, a B-cell surface marker with broader expression than CD20. This is a critical distinction: CD20 is absent on antibody-producing plasmablasts and plasma cells, whereas CD19 is expressed across a wider B-cell lineage spectrum including these antibody-secreting cells. By depleting both conventional B cells and plasmablasts, inebilizumab may more effectively reduce pathogenic antibody production.

FDA approved: 2020, for AQP4-IgG-positive NMOSD
Dosing: 300 mg IV on days 1 and 15 (induction), then 300 mg IV every 6 months
Key trial: N-MOmentum — demonstrated a 77% reduction in NMOSD attacks vs placebo
Advantage over rituximab: Depletes CD20-negative plasmablasts and plasma cells that continue to produce pathogenic antibodies
Screening and monitoring: Similar to rituximab — hepatitis B/C, TB, quantitative immunoglobulins
Adverse effects: Infection risk, hypogammaglobulinemia, infusion reactions

Satralizumab (Anti-IL-6 Receptor)

Satralizumab is a recycling monoclonal antibody that inhibits IL-6 receptor signaling. IL-6 is a key cytokine in NMOSD pathogenesis that promotes plasmablast survival, Th17 differentiation, and antibody production. By blocking IL-6 signaling, satralizumab disrupts these pro-inflammatory cascades without broadly depleting immune cells.

FDA approved: 2020, for AQP4-IgG-positive NMOSD; also being studied in MOGAD
Dosing: 120 mg SC at weeks 0, 2, 4 (induction), then every 4 weeks
Key trials: SAkuraStar (monotherapy) and SAkuraSky (add-on) — both demonstrated significant relapse risk reduction in AQP4-positive patients
Flexibility: Can be used as monotherapy or with conventional immunosuppressants
Pediatric data: Limited (8 patients aged 12–18 enrolled in trials)
Advantages: Subcutaneous administration; favorable safety profile compared to broad immunosuppression
Adverse effects: URIs, injection site reactions, headache, elevated liver enzymes, hypertension, lipid elevation, neutropenia

Eculizumab (Anti-C5 Complement)

Eculizumab inhibits terminal complement activation by blocking C5 cleavage, preventing formation of the membrane attack complex (MAC). In AQP4-NMOSD, complement-mediated astrocyte injury is a central pathogenic mechanism, making complement inhibition a rational therapeutic target. Eculizumab demonstrated the most robust efficacy of any agent tested in an NMOSD randomized controlled trial.

FDA approved: 2019, for AQP4-IgG-positive NMOSD (also approved for myasthenia gravis and other complement-mediated conditions)
Dosing: 900 mg IV weekly × 4 (induction), then 1200 mg at week 5, then 1200 mg every 2 weeks
Key trial: PREVENT — 94% reduction in relapse risk vs placebo in AQP4-positive NMOSD
Monitoring: CBC, liver enzymes, watch for signs and symptoms of meningococcal infection
Adverse effects: Headache, URIs, infusion reactions, meningococcal infection (black box warning)
Cost: Extremely expensive (~$500,000/year)

Meningococcal Vaccination Before Complement Inhibitors

Meningococcal vaccination is REQUIRED at least 2 weeks before starting eculizumab or ravulizumab
Complement inhibition dramatically increases the risk of meningococcal infection (Neisseria meningitidis) — carries a black box warning
Both MenACWY and MenB vaccines should be administered
Some guidelines recommend prophylactic antibiotics (penicillin or ciprofloxacin) in addition to vaccination
Patients must be educated about symptoms of meningococcal infection and instructed to seek immediate medical attention

Ravulizumab (Long-Acting Anti-C5)

Ravulizumab is an extended half-life version of eculizumab that requires administration every 8 weeks instead of every 2 weeks, offering substantially improved convenience with the same mechanism of action. Weight-dependent dosing is used. Ravulizumab is being studied in NMOSD and other complement-mediated conditions and may replace eculizumab as the preferred complement inhibitor due to its more practical dosing schedule. The same meningococcal vaccination requirements apply.

Tocilizumab (Anti-IL-6 Receptor)

Tocilizumab is an IL-6 receptor inhibitor with an overlapping mechanism to satralizumab but different pharmacokinetics. Unlike satralizumab, tocilizumab is not FDA-approved for NMOSD but is used off-label across several neuroimmunologic conditions, particularly in refractory cases.

Dosing: 4–8 mg/kg IV every 4 weeks, or 162 mg SC every 1–2 weeks
Off-label indications: NMOSD (especially AQP4-positive), refractory autoimmune encephalitis, fulminant MOGAD, neurosarcoidosis
Key evidence: Phase 2 TANGO trial demonstrated superiority over azathioprine in preventing AQP4-NMOSD relapses
Screening: Hepatitis B/C, TB (IGRA)
Monitoring: CBC, liver enzymes, fasting lipids
Adverse effects: URIs, injection/infusion reactions, headache, elevated liver enzymes, hypertension, lipid elevations, neutropenia

Infliximab (Anti-TNF-α)

Infliximab is a chimeric monoclonal antibody targeting TNF-α, a key pro-inflammatory cytokine involved in granuloma formation and maintenance. In neuroimmunology, infliximab has emerged as a cornerstone therapy for neurosarcoidosis, where the current trend favors early initiation of infliximab combined with methotrexate as the preferred steroid-sparing approach.

Infliximab in Neurosarcoidosis

Dosing: 3–5 mg/kg IV at weeks 0, 2, and 6 (induction), then every 4–8 weeks (maintenance)
Preferred combination: Infliximab + methotrexate — methotrexate both enhances efficacy and prevents formation of anti-infliximab antibodies
Other indications: Neuro-Behcet disease
Pre-treatment screening: TB (IGRA), hepatitis B
Monitoring: Regular CBC
Adverse effects: Infusion reactions, increased infection risk

TNF-α Inhibitors and Demyelination

TNF-α inhibitors (infliximab, adalimumab) may increase the risk of demyelination, including new-onset MS-like disease in patients with rheumatoid arthritis
Do NOT use TNF-α inhibitors for MS or NMOSD
TNF-α inhibitors are appropriate for neurosarcoidosis and neuro-Behcet disease, where their anti-granulomatous and anti-inflammatory effects outweigh this risk
If demyelinating symptoms develop during TNF-α inhibitor therapy, discontinue immediately and evaluate for MS or NMOSD

Adalimumab (Anti-TNF-α)

Adalimumab is a fully human anti-TNF-α monoclonal antibody administered as 40 mg SC every 2 weeks. It shares similar indications to infliximab for neurosarcoidosis and can be considered as an alternative, particularly when subcutaneous administration is preferred. The same demyelination warning applies to adalimumab as to infliximab.

MS Disease-Modifying Therapies — Overview

Multiple sclerosis disease-modifying therapies (DMTs) are covered in detail in the dedicated MS topics. This section provides a brief comparative overview for context within the broader immunosuppression landscape. The key principle in current MS treatment is the growing consensus favoring early high-efficacy therapy over traditional escalation approaches, as early aggressive treatment may reduce long-term disability accrual.

Category	Agents	Efficacy
Platform therapies	Interferons (IFN-β1a, IFN-β1b), glatiramer acetate	Moderate efficacy; well-established long-term safety
Oral therapies	Fingolimod, siponimod, dimethyl fumarate, diroximel fumarate, teriflunomide, cladribine	Moderate to high efficacy depending on agent
High-efficacy infusion/injection	Natalizumab (anti-VLA4), ocrelizumab (anti-CD20), ofatumumab (anti-CD20), ublituximab (anti-CD20), alemtuzumab (anti-CD52)	High efficacy; used as first-line or after breakthrough on lower-efficacy agents

MS DMTs Contraindicated in NMOSD

MS disease-modifying therapies are contraindicated in NMOSD
Interferon-beta can exacerbate NMOSD relapses
Natalizumab is associated with disease exacerbation in NMOSD
Fingolimod has been reported to worsen NMOSD disease activity
Accurate differentiation between MS and NMOSD is critical before initiating any disease-modifying therapy
Always test for AQP4-IgG (and MOG-IgG) before starting MS-specific treatments, particularly in patients with atypical presentations

Comprehensive Drug Comparison

Drug	Mechanism	Route	Dosing Frequency	Key Screening	Major Adverse Effects	Primary Neuroimmunology Indications
Mycophenolate mofetil	IMPDH inhibitor; depletes guanosine nucleotides in lymphocytes	Oral	Twice daily	CBC, liver/renal function, pregnancy	GI symptoms, myelosuppression, teratogenicity, infection risk	NMOSD, MOGAD, autoimmune encephalitis, neuropsychiatric SLE, neurosarcoidosis
Azathioprine	Purine synthesis inhibitor	Oral	Daily	CBC, liver function, TPMT genotype, pregnancy	Myelosuppression (TPMT-dependent), liver toxicity, pancreatitis, malignancy risk	NMOSD, MOGAD, neurosarcoidosis, autoimmune encephalitis
Methotrexate	Dihydrofolate reductase inhibitor	Oral/SC	Weekly	CBC, liver/renal function, pregnancy	Hepatotoxicity, myelosuppression, teratogenicity, leukoencephalopathy	Neurosarcoidosis (with infliximab)
Rituximab	Anti-CD20; B-cell depletion	IV	Every 6 months	Hepatitis B/C, TB (IGRA), immunoglobulins	Infusion reactions, hypogammaglobulinemia, infection risk, PML (rare)	NMOSD, MOGAD, autoimmune encephalitis, neurosarcoidosis, CNS vasculitis, IgG4-RD
Inebilizumab	Anti-CD19; B-cell and plasmablast depletion	IV	Every 6 months	Hepatitis B/C, TB, immunoglobulins	Infection risk, hypogammaglobulinemia, infusion reactions	AQP4+ NMOSD (FDA-approved)
Satralizumab	Anti-IL-6 receptor (recycling antibody)	SC	Every 4 weeks	Hepatitis B/C, TB, liver function	URIs, injection site reactions, liver enzyme elevation, lipid elevation	AQP4+ NMOSD (FDA-approved)
Eculizumab	Anti-C5; terminal complement inhibition	IV	Every 2 weeks	Meningococcal vaccination, CBC	Meningococcal infection (black box), headache, infusion reactions	AQP4+ NMOSD (FDA-approved)
Ravulizumab	Anti-C5; extended half-life complement inhibitor	IV	Every 8 weeks	Meningococcal vaccination, CBC	Same as eculizumab	Under study for NMOSD; approved for other complement-mediated diseases
Tocilizumab	Anti-IL-6 receptor	IV/SC	Every 4 weeks (IV) or every 1–2 weeks (SC)	Hepatitis B/C, TB, liver function, lipids	Infection risk, liver enzyme elevation, lipid elevation, neutropenia	Refractory NMOSD, refractory autoimmune encephalitis, fulminant MOGAD, neurosarcoidosis
Infliximab	Anti-TNF-α	IV	Every 4–8 weeks	TB (IGRA), hepatitis B	Infusion reactions, infection risk, demyelination risk	Neurosarcoidosis, neuro-Behcet disease
Adalimumab	Anti-TNF-α	SC	Every 2 weeks	TB (IGRA), hepatitis B	Injection site reactions, infection risk, demyelination risk	Neurosarcoidosis

Treatment Selection Considerations

Selecting the appropriate maintenance immunotherapy requires careful consideration of multiple disease-specific and patient-specific factors. The following framework guides treatment decisions across neuroimmunologic conditions.

Disease-Specific Treatment Guidelines

AQP4-positive NMOSD: FDA-approved biologics (satralizumab, inebilizumab, eculizumab) are preferred when accessible; rituximab remains the most widely used agent worldwide; oral immunosuppressants (azathioprine, mycophenolate) are alternatives in resource-limited settings
MOGAD: Treatment required only for relapsing disease; rituximab, mycophenolate, and azathioprine are most commonly used; satralizumab is under investigation; IVIg may be effective for relapse prevention
Multiple sclerosis: High-efficacy DMTs (natalizumab, ocrelizumab, ofatumumab, ublituximab, alemtuzumab) increasingly favored early; MS DMTs are contraindicated in NMOSD
Autoimmune encephalitis: Rituximab is the most commonly used second-line agent for maintenance; mycophenolate and azathioprine are alternatives
Neurosarcoidosis: Infliximab + methotrexate is the preferred steroid-sparing combination; adalimumab is an alternative anti-TNF-α agent
CNS vasculitis: Rituximab, cyclophosphamide, or mycophenolate depending on severity and etiology
Neuropsychiatric SLE: Hydroxychloroquine for all SLE patients; mycophenolate, azathioprine, or rituximab for active CNS disease

Antibody Subclass and Treatment Implications

The IgG subclass of the pathogenic antibody has important implications for treatment selection:

Feature	IgG1 Disorders	IgG4 Disorders
Examples	NMDA-R encephalitis, AQP4-NMOSD	LGI1 encephalitis, CASPR2 encephalitis
Complement activation	Yes — IgG1 activates classical complement pathway	No — IgG4 does NOT activate complement
Complement inhibition	May respond to complement inhibitors (e.g., eculizumab in AQP4-NMOSD)	Complement inhibitors are NOT expected to be effective
Pathogenic mechanism	Complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity	Direct functional blockade of target antigen

Practical Considerations

Cost and access: FDA-approved NMOSD biologics and complement inhibitors are extremely expensive; rituximab and oral immunosuppressants are more widely accessible; insurance coverage and patient assistance programs should be explored
Route of administration: Subcutaneous agents (satralizumab, adalimumab, ofatumumab) offer convenience over IV infusions; oral agents (mycophenolate, azathioprine, methotrexate) avoid infusion-related logistics entirely
Family planning: Many immunosuppressants are teratogenic (mycophenolate, azathioprine, methotrexate); pregnancy timing must be coordinated with treatment plans; some biologics (rituximab) require washout periods before conception; satralizumab and eculizumab have limited pregnancy data
Comorbidities: Hepatitis B reactivation risk with B-cell depleting agents; infection susceptibility with hypogammaglobulinemia; cardiovascular and metabolic risk with chronic corticosteroids

Long-Term Monitoring

All patients on chronic immunosuppression require structured long-term monitoring to detect adverse effects early and maintain safe, effective therapy.

Monitoring Protocol for Chronic Immunosuppression

CBC with differential: Every 1–3 months initially, then every 3–6 months once stable; detect myelosuppression and cytopenias
Quantitative immunoglobulins (IgG, IgM, IgA): Every 6–12 months for patients on B-cell depleting therapies; more frequently if recurrent infections; consider IgG replacement if IgG is low and infections recur
Liver function tests: Baseline and every 3–6 months for methotrexate, azathioprine, mycophenolate, tocilizumab, satralizumab
Renal function: Baseline and periodically for methotrexate and mycophenolate
Fasting lipid panel: Baseline and periodically for IL-6 receptor inhibitors (tocilizumab, satralizumab) which can elevate lipids
Infection surveillance: Annual TB screening for patients on TNF-α inhibitors; hepatitis B monitoring for patients on B-cell depleting agents; promptly evaluate fever and constitutional symptoms
Malignancy screening: Age-appropriate cancer screening; increased vigilance for non-melanoma skin cancer and lymphoma with azathioprine; annual dermatologic examination recommended
Vaccination: Update vaccinations before starting immunosuppression when possible; live vaccines are generally contraindicated during immunosuppressive therapy; annual influenza and pneumococcal vaccination recommended

References

McKeon A, Pittock SJ. Overview and diagnostic approach in autoimmune neurology. Continuum (Minneap Minn). 2024;30(4):960-994.
Sechi E, Flanagan EP. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Continuum (Minneap Minn). 2024;30(4):1052-1090.
McCombe JA. Neurologic manifestations of rheumatologic disorders. Continuum (Minneap Minn). 2024;30(4):1189-1225.
Hacohen Y. Pediatric autoimmune neurologic disorders. Continuum (Minneap Minn). 2024;30(4):1160-1188.